Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus QAB149 safety study in moderate to severe COPD
2012-001998-93Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of indacaterol, glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Oct 2012; status: completed.
02
Drugs
indacaterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-001998-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001998-93.